Abstract 461P
Background
Lung cancer is the leading cause of cancer deaths worldwide including in India. Around 80% of these are Non Small Cell Lung Cancers (NSCLC) detected in advanced stages where surgical resection is not an option and locally advanced stage patients are treated with concurrent chemoradiotherapy.
Methods
A total of 90 patients of NSCLC Stages IIIA and IIIB participated in the study conducted over the last eighteen months. They were randomized and distributed between two arms in 1:1 ratio. Their pre-treatment Pulmonary Function Tests were recorded. Participants in Arm A underwent 30 minutes of yoga session daily besides standard fractionation radiotherapy with concurrent weekly chemotherapy. Participants in Arm B received the same schedule of concurrent chemoradiotherapy but without the daily yoga session. Their post-treatment Pulmonary Function Tests were recorded at six weeks post completion of chemoradiotherapy and compared with pre-treatment values.
Results
21 participants in Arm A recorded positive changes in their FEV1 values, compared to just 3 patients in Arm B (p=0.0002), suggesting daily yoga sessions during treatment can actually help in improvement of lung function among locally advanced NSCLC patients.
Conclusions
Further multi-institutional studies with more participants should be encouraged and yoga be more maistreamed and formally incoporated into standard therapeutic regimens for the management of locally advanced non small cell lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract